(Q38103889)

28 August 2017

title

Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections (English)

1 reference

28 August 2017

1 reference

2

1 reference

28 August 2017

Jodi Lestner

1

0 references

language of work or name

English

0 references

publication date

6 May 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

number of pages

16

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

911-926

1 reference

Itraconazole, a new triazole that is orally active in aspergillosis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Therapeutic outcome in invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole therapy for chronic coccidioidal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

21 January 2018

Intravenous itraconazole

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

The effect of parenterally administered cyclodextrins on cholesterol levels in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Chitosan-coated liposomes for intracellular oligonucleotides delivery: characteristics and cell uptake behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Development and evaluation of novel itraconazole-loaded intravenous nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Generation of a complete, soluble, and catalytically active sterol 14 alpha-demethylase-reductase complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Homology modeling of lanosterol 14alpha-demethylase of Candida albicans and Aspergillus fumigatus and insights into the enzyme-substrate Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

An improved model of the Aspergillus fumigatus CYP51A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Azole resistance by loss of function of the sterol Δ⁵,⁶-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Acquired itraconazole resistance in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR₃₄/L98H mutations in the cyp51A gene in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Pharmacokinetics of itraconazole following oral administration to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Stereochemical aspects of itraconazole metabolism in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Optimisation of itraconazole therapy using target drug concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Cyclophosphamide metabolism is affected by azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Efficacy and safety of posaconazole for chronic pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole for the treatment of onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

The pharmacokinetics of oral itraconazole in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Itraconazole pharmacokinetics in patients with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Toxicodynamics of itraconazole: implications for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Cardiovascular adverse effects during itraconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Congestive heart failure associated with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Hepatic injury associated with itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Peripheral neuropathy in patients on long-term triazole antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Severe hypokalemia and rhabdomyolysis associated with itraconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Therapeutic drug monitoring for triazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.794785

10.1517/17425255.2013.794785

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference